NCT06308653 - Psilocybin for Major Depressive Disorder (MDD)
Clinical Trial in Birmingham, Alabama
Approximately 240 eligible adult participants (>=18 years old) who meet Diagnostic and Statistical Manual of Mental Disorders (DSM-5-TR) criteria for Major Depressive Disorder (MDD) will be enrolled. Participants will be randomly assigned to receive a single oral dose of Psilocybin 25 mg, Psilocybin 5 mg, or inactive placebo. The purpose of this study is to evaluate the efficacy, safety, and tolerability of Psiloc... Source record lists lead sponsor Usona Institute and overall status Active Not Recruiting.
Last verified: 2026-06-12